Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma
Stefan Alig(Heidelberg University), Ash A. Alizadeh(California Institute for Regenerative Medicine), Alexander Craig(Stanford University), Mohammad Shahrokh Esfahani(Stanford Medicine), Michel Meignan(Délégation Paris 5), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Joanne Soo(Stanford Medicine), Barzin Y. Nabet(Gene Therapy Laboratory), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Mark Roschewski(National Cancer Institute), Wyndham H. Wilson(National Institutes of Health), Florian Scherer(German Cancer Research Center), Charles Macaulay(Stanford Medicine), Olivier Casasnovas, Brian J. Sworder(City Of Hope National Medical Center), David M. Kurtz(Stanford University), Andreas Hüttmann(University of Duisburg-Essen), Michael C. Jin(Stanford University), Ulrich Dührsen(Essen University Hospital), Maximilian Diehn(Stanford University), Andrea Garofalo(Stanford University), Christine Hanoun(Essen University Hospital)
Cited by 78
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k